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Highly specific and selective anti-pS396-tau antibody C10.2 targets
seeding-competent tauNina Rosenqvista, Ayodeji A. Asunia, Christian R. Anderssona, Søren Christensena,
Justus A. Daechsela, Jan Egebjerga, Jeppe Falsiga, Lone Helboea, Pia Jula, Fredrik Kartberga,
Lars Ø. Pedersena, Einar M. Sigurdssonb,c, Florence Sottya, Karsten Skjødtd,
Jeffrey B. Stavenhagene, Christiane Volbrachta, Jan T. Pedersena,*
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eTherachon AG, Basel, SwitzerlandAbstract Introduction: The abnormal hyperphosphorylation of the microtubule-associated protein tau plays a*Corresponding au
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https://doi.org/10.1016
2352-8737/ 2018 T
license (http://creativecrucial role in neurodegeneration in Alzheimer’s disease (AD) and other tauopathies.
Methods: Highly specific and selective anti-pS396-tau antibodies have been generated using peptide
immunization with screening against pathologic hyperphosphorylated tau from rTg4510 mouse and
AD brains and selection in in vitro and in vivo tau seeding assays.
Results: The antibody C10.2 bound specifically to pS396-tau with an IC50 of 104 pM and detected
preferentially hyperphosphorylated tau aggregates from AD brain with an IC50 of 1.2 nM. C10.2
significantly reduced tau seeding of P301L human tau in HEK293 cells, murine cortical neurons,
and mice. AD brain extracts depleted with C10.2 were not able to seed tau in vitro and in vivo,
demonstrating that C10.2 specifically recognized pathologic seeding-competent tau.
Discussion: Targeting pS396-tau with an antibody like C10.2 may provide therapeutic benefit in AD
and other tauopathies.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Anti-tau antibodies; Phospho-serine 396; Tau seeding; Monoclonal antibody; C10.2; D1.2; C5.2; C8.31. Introduction
Microtubule-associated protein tau deposited as straight
and paired helical filaments (PHFs) form the neurofibrillary
tangles (NFTs), one of the hallmarks of Alzheimer’s disease
(AD) [1]. These tau aggregates are detergent-insoluble and
contain predominantly hyperphosphorylated tau [2]. The
longest isoform of tau (2N4R or Tau-441) contains 85 puta-
tive phosphorylation sites (Ser, Thr, or Tyr) and of these, halfthor. Tel.: 145 30832887; Fax: 145 36438258.
tp@lundbeck.com
/j.trci.2018.09.005
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).have been confirmed experimentally [3]. Phosphorylation
sites are located mainly around the microtubule binding
(MTB) domains, and tau is dynamically phosphorylated
and dephosphorylated by several kinases and phosphatases.
Tau associates with microtubules in its dephosphorylated
form, thereby acting as a stabilizer regulating axonal trans-
port [3]. Under normal conditions, cytosolic tau contains,
on average, two to three phosphorylated sites [4]. In paired
helical and straight filamentous material tau is hyperphos-
phorylated, with at least seven sites phosphorylated [4,5].
Braak and Braak [6] and Nelson et al. [7] demonstrated
that the spatiotemporal appearance of NFTs closely follows
the development of neurodegeneration and clinicalimer’s Association. This is an open access article under the CC BY-NC-ND
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from dead neurons, appear in more advanced stages of AD
[8]. The spatiotemporal spreading of tau pathology suggests
that tau itself may form an endopathogen species, which
propagates pathology from one neuron to adjacent cells.
Clavaguera et al. [9] demonstrated that aggregated hyper-
phosphorylated tau isolated from transgenic mouse brains
acts as a mediator of tau seeding and on hippocampal injec-
tion induces tau pathology in transgenic mice (ALZ17)
otherwise lacking tau aggregates. Also, peripheral injection
of brain extracts from old tau transgenic mice increased
tangle pathology [10]. Recent biochemical and in vivo seed-
ing studies demonstrated that small tau fibrils likely are the
main seeding and propagating species [11–13].
Furthermore, cryo-electron microscopy [14] studies have
demonstrated that a cross-b/b-helix structure covering resi-
dues 306 to 378 constitutes a tau aggregate core and may
be the seeding competent species for propagation of tau pa-
thology in AD and other tauopathies. Thus, seeding-
competent pathologic tau species could represent a viable
therapeutic target. Active vaccination studies with tau pep-
tides indicated that raising an immune response against spe-
cific phosphorylated epitopes of tau could prevent the
formation of tau pathology in tau transgenic mouse models
[15–20]. Subsequently, passive immunization with
different phospho-dependent and phospho-independent tau
antibodies was reported to reduce tau pathology in different
tau transgenic mouse models [21–31]. In this report, we
describe the generation of pS396-tau specific antibodies
and demonstrate in vitro and in vivo evidence that suggest
anti-pS396 antibodies have a therapeutic potential to prevent
seeding of tau pathology.2. Materials and methods
2.1. Generation of antibodies
Male and female mice (C57BL/6 and FVB strains)
were immunized with peptide P30-pS396/pS404-tau;
containing the P30 (tetanus toxin P30 helper peptide
epitope, FNNFTVSFWLRVPKVSASHLEGPSL) and
phosphorylated tau (386–408) peptide corresponding to the
sequence P30-[TDHGAEIVYK(pS)PVVSGDT(pS)PRHL]
(US patent, US2008050383). P30-pS396/pS404-tau was
formulated in TiterMax Gold Adjuvant from Sigma-
Aldrich (400 mg/mL peptide mixed 1:1 vol/vol) following
the manufacturer’s protocol, and 20 mg peptide antigen
(100 mL) was injected subcutaneously. All peptide-
immunized mice were boosted with 0.5 mg P30-pS396/
pS404-tau/TiterMax four times at monthly intervals. The
mice were finally boosted with 0.5 mg P30-pS396/pS404-
tau (without TiterMax) 3 days before fusion of splenocytes
with SP-2 cells. Hybridomas exhibiting positive binding to
enzyme-linked immunosorbent assay plates (Nunc Maxi-
sorp) coated with 1 mg/mL pS396/pS404-tau in coating
buffer (carbonate buffer, pH 9.4) were selected forrecloning. By this procedure, three clones were generated
(C10.2, C10.1 from C57/BL6, and D1.2 from FVB mice)
and characterized in subsequent range of assays. In
addition, the following antibodies were included: PHF13
(tau-p396, Thermo Fisher Scientific); AT8 (tau-p202/p205,
Thermo Fisher Scientific); Tau 5 (total tau, Thermo Fisher
Scientific); E1 (human-specific tau (19–33), generated in
rabbit [32].2.2. Analysis of peptide binding2.2.1. Peptide competition binding assay
Meso Scale discovery (MSD) plates were coated over-
night at 4C with 100 ng/mL of peptide tau (386–408)-
pS396/pS404 in coating buffer, blocked for 1 hour at
25C, and washed three times (0.1% bovine serum albumin
[fraction V], 0.1%NP40 in phosphate buffered saline (PBS),
pH 7.4). Low concentrations of tau-pS396–specific anti-
bodies (typically 0.1!Kd, e.g., 1–2 ng/mL or lower to avoid
ligand depletion) were incubated 1:1 with graded concentra-
tions (1 hour at 22C) of tau (386–408)-pS396/pS404, fol-
lowed by washing three times and finally subjected to
analysis of unbound antibody in tau (386–408)-pS396/
pS404–coated MSD plates. Antibody binding in wells was
detected using MSD Sulfotag goat anti-mouse immunoglob-
ulin G (IgG) antibody (catalog no R32AC-1) at 1:500 dilu-
tion. Inhibition curves and IC50 values were obtained by
fitting to one site binding models using GraphPad Prism soft-
ware. One hundred nanometers of tau (386–408)-pS396, tau
(386–408)-pS404, tau (260–270)-pS262, or nonphosphory-
lated tau (386–408) were tested for inhibition of antibody
binding in parallel and compared with tau (386–408)-
pS396/pS404 inhibition curve.
2.2.2. Surface plasmon resonance Biacore analysis
The antibodies were tested for binding to monophos-
phorylated tau (386–408)-pS396 and double phosphorylated
pS396/pS404-tau peptides. Nonphosphorylated tau (386–
408) was used as nonbinding peptide control. Antibodies
were captured on CM5 sensor chips coated with anti-
mouse IgG antibody (GE catalog no BR100838). The tau
peptides were initially screened for binding at their top con-
centrations. Subsequently, peptides demonstrating binding
were titrated into the captured antibodies. The titration
was performed twice. For each antibody and peptide interac-
tion, the sensorgrams were fit globally to a simulated 1 to 1
kinetics binding model using the BiaEvaluation software
(estimated kon, koff, and Kd from the fit are reported in
Table 1).2.3. Mouse tissue
The rTg4510 transgenic mice express human 4-repeat
mutant P301L tau [33]. The mouse colony was bred and
housed as described earlier [34]. Single-transgenic tTA
Table 1
SPR Biacore peptide binding
Antibody
Tau
386–408
peptide
Peptide
MW (Da)
Average of
expected
Rmax (RU)
Average of
Rmax (RU)
Average
kon (1/ms)
SD_kon
(1/ms)
Average
koff (1/s)
SD_koff
(1/s)
Kd
(nM)
SD Kd
(nM)
Average
stoichiometry
D1.2 pS396 2560 9 10 2.3! 106 2.8! 104 2.4! 1022 1024 11 0.1 1.0
pS396/pS404 2624 10 10 1.7! 106 7.1! 103 2.6! 1022 1023 15 0.6 1.0
C10.2 pS396 2560 6 8 2.8! 106 1.6! 105 7.4! 1022 7! 1023 27 1.3 1.3
pS396/pS404 2624 7 8 2.2! 106 2.7! 105 6.7! 1022 1024 31 3.8 1.2
Abbreviations: SD, standard deviation; SPR, surface plasmon resonance.
On (kon) and off (koff) rates andKd were determined. TheKd for the pS396 peptide is virtually identical to that for the diphosphorylated peptide pS396/pS404
indicating clear specificity for pS396.
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trol subjects. All animal experiments were performed in
accordance with the European Communities Council Direc-
tive no. 86/609, the directives of the Danish National Com-
mittee on Animal Research Ethics, and Danish legislation on
experimental animals (license no. 2014-15-0201-00339).
Mice were euthanized by cervical dislocation, the brains
were quickly removed and parted from the cerebellum and
hind brain. The forebrain containing the cerebral cortex
and hippocampus was snap-frozen on dry ice and stored at
280C until use. For in vitro and in vivo seeding material,
we used pooled brains from rTg4510 or tTA mice aged 36
to 40 weeks when tau pathology was advanced in the fore-
brain.
2.4. Human tissue
Frozen samples of frontal cortices from AD and healthy
control (HC) cases were acquired from Tissue Solutions
(United Kingdom). Gray matter tissue was isolated and
pooled from two (seeding) or four (dot blot) AD and four
HC cases. Subject characterization can be found in
Supplementary Table 1.
2.5. Tissue extraction and fractionation
The soluble S1 and insoluble P3 preparations were per-
formed as described earlier [35]. Tau fractions used as seeds
in vitro were prepared from rTg4510 forebrains omitting
protease and phosphatase inhibitors and ion chelators in
the buffers. For solution phase binding, P3 fractions were
prepared from AD frontal cortices. For in vivo seeding,
crude extracts were prepared from rTg4510 and tTA litter-
mate mice and from human AD and HC cortical tissue as
described by Clavaguera et al. [9].
2.6. Solution phase antibody binding to AD P3 material
and recombinant phosphorylated tau-441
MSD plates were coated overnight at 4Cwith 0.5 mg/mL
C10.2 (capture antibody) in coating buffer, blocked for
1 hour at 25C, and washed three times. P3 fraction from
AD cortex diluted 1:1000 (2–4 mg/mL total protein) or
30 ng/mL recombinant phosphorylated tau (SignalChem,tau-441 glycogen synthase kinase 3 beta-phosphorylated
(T08-50FN)) and graded concentrations (0–300 nM) of
C10.2, D1.2, PHF13, and C10.1 (negative control), respec-
tively, were incubated for 1 hour at 22C followed by
washing three times. C10.2-captured tau was detected using
a 1:50 diluted anti-tau antibody (Sulfotag goat anti-total tau
antibody, MSD catalog no R32AC-1).
2.7. Dot blot
One microliter of samples S1 and P3 isolated from AD
and HC cortices or from rTg4510 and tTA brains were
applied to nitrocellulose membranes. After blocking with
5% nonfat milk and 0.1% Triton X-100 in Tris-buffered sa-
line, the membranes were incubated with 1 mg/mL D1.2 or
C10.2. Membranes were washed and incubated with
peroxidase-conjugated anti-mouse antibody (1:5000; Jack-
son ImmunoResearch). Bound antibodies were detected us-
ing an enhanced chemiluminescence system (ECL PLUS
kit; Perkin Elmer).
2.8. Immunohistochemistry on human brain sections
Formalin-fixed paraffin-embedded frontal cortex from
three AD (Braak stage V–VI) and three age-matched HC
cases were acquired from tissue solutions. Subject character-
ization can be found in Supplementary Table 1. Four-
micrometer sections were deparaffinized, rehydrated, and
subjected to antigen retrieval by boiling in 10 mM citrate
buffer, pH 6. The sections were incubated overnight at 4C
with C10.2, D1.2, or C10.1 antibodies at 1 mg/mL. After
thorough rinsing, sections were incubated with biotinylated
anti-mouse antibodies (Dako). Immunoreactivity was visu-
alized using the avidin-biotin complex (Vector) and 0.05%
3,30-diaminobenzidine. Sections were counterstained with
hematoxylin.
2.9. Immunodepletion for seeding
One hundred micrograms of antibody was immobilized
to 500 mL of magnetic Dynabead suspension (Immunopre-
cipitation Kit Dynabeads Protein G Novex, catalog no
10007D). After thorough washing, the beads were mixed
with 100 mL crude extract of rTg4510 or AD frontal cortex
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temperature for 10 minutes. The magnetic beads were sepa-
rated from the extract, and extracts were aliquoted, snap
frozen, and stored at 280C until use.
2.10. Primary neuronal culture
Cortical cultures (CTXs) were isolated from day 14 to 16
tTA or rTg4510 mouse embryos as described previously
[36]. Embryos were genotyped using primer pairs as
described [33]. Neurons were cultured in glia-conditioned
neurobasal medium supplemented with 2% B-27 supple-
ment with antioxidants, 0.5 mM L-glutamine, 100 U/mL
penicillin, 0.1 mg/mL streptomycin (all solutions from
Gibco-BRL Invitrogen) and treated with 1 mM cytosine
arabinoside at days in vitro (DIV) 4 to halt proliferating
cells. The proportion of glia cells in the cultures was less
than 10%, as assessed by an antibody against glia-
fibrillary-acidic protein at DIV7.
2.11. Tau and antibody uptake in tTA neurons
At DIV7, CTXs isolated from tTAmouse embryos were
treated with a mixture of 2 ng human tau from rTg4510 P3
fractions and 10 mg antibodies (D1.2, C10.2, C10.1, and
mouse IgG control) or PBS. The tau seed/antibody
mixture was preincubated for 2 hours at 4C before adding
to CTX. After 24 hours, the cells were washed, fixed in
3.7% formaldehyde, and immunostained for human tau
using the E1 antibody and for mouse immunoglobulins
with anti-mouse IgG antibody conjugated with Alexa
Fluor 546 (Molecular Probes). Anti-rabbit IgG conjugated
with Alexa Fluor 488 (Molecular Probes) was used as the
secondary antibody to detect the E1 signal. Nuclei were
counterstained with Hoechst 33342. Human tau and anti-
body uptake was detected by image processing software
using a spot-detection algorithm on the charge-coupled
device camera-based ArrayScan VTI HCS system (Cello-
mics Scan software version 6.5). Twenty microscopic
fields were analyzed per well and data quantified as spots
per cell.
2.12. Tau seeding in rTg4510 neurons
At DIV7, CTXs isolated from rTg4510 mouse embryos
were treated with a mixture of 0.2 ng human tau from
rTg4510 P3 fractions and 10 mg antibodies (D1.2, C10.2,
C10.1, and mouse IgG control) or PBS. The tau seed/anti-
body mixture was preincubated for 2 hours at 4C before
adding to CTX. At DIV11, a complete medium change
was performed to remove any residual tau and antibody.
At DIV15, neurons were lysed in ice-cold lysis buffer (1%
Triton X-100 in 50 mM Tris, 150 mM NaCl (pH 7.6) with
1% protease inhibitor mixture [Roche], 1% phosphatase in-
hibitor cocktail I and II [Sigma], and 0.2% Benzonase
[Sigma]) under shaking at 200 rpm for 45 minutes at 4C.
Lysates were used in the Cisbio tau aggregation and bicin-choninic acid assays according to manufactures’ instruc-
tions.
For detection of cell viability after P3 and antibody addition,
the percentage of viable cells in the neuronal cultures was
quantified at DIV15 from parallel plates by their capacity to
reduce 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) after incubation with 0.5 mg/mL MTT for
60 minutes.2.13. In vivo seeding
To establish a window for detection of seeding-induced
tau pathology in the rTg4510 model the development of
tau phosphorylation and tangle formation was delayed
by suppressing tau transgene expression with doxycycline
(as described in Refs. [33,34]). We established that the
presence of doxycycline from conception until the age
of 3 weeks delayed tau phosphorylation in hippocampus
at age from 16 weeks until around 24 weeks, thus
providing enough time for seeding-induced tau pathology
to develop before interference from endogenous tau
pathology.
Seeding: doxycycline-treated rTg4510 and tTA mice
were seeded at the age of 10 weeks as follows: mice were
anesthetized by isoflurane inhalation and fixed in a stereotac-
tic frame. The dural surface was carefully exposed and 2 mL
crude extracts prepared from rTg4510, tTa, AD, or HC
brains were slowly infused (1 mL/min) using a 10 mL syringe
with a 26 gauche, beveled tip into the right hippocampus at
the following coordinates: M/L, 22.0; A/P, 22.4; V, 21.4
from bregma and the dural surface. The wound was closed
and sealed with sutures and mice were homeothermally sup-
ported during recovery from anesthesia. Mice were then
housed for 4 to 12 weeks before being perfusion-fixed
with 4% paraformaldehyde.
Antibody treatment and blood sampling: antibodies
(C10.2, D1.2, or control mouse IgG) were prepared in a con-
centration of 1.5 mg/mL in sterile PBS. At age from 8 weeks
(2 weeks before seeding with rTg4510 or tTA crude extracts)
until euthanization at 22 weeks the mice received one
weekly intraperitoneal (ip) dose of antibody (15 mg/kg).
Blood samples were drawn every 2 to 4 weeks and the con-
centration of antibody in plasma was analyzed by enzyme-
linked immunosorbent assay using a phosphorylated tau
peptide (386–408, pS396/pS404 from TAG, Denmark) as
capture and a Sulfotag goat anti-mouse antibody for detec-
tion (MSD catalog no R32AC-1). In a seeding experiment
comparing three different dosing paradigms, C10.2 anti-
bodies (15 mg/kg, ip) were dosed once weekly at age from
8 to 22 weeks (full), once weekly at age from 14 to 22 weeks
(post), or once weekly at age from 8 to 10 weeks (pre). A
control mouse IgG was dosed once weekly at age from 8
to 22 weeks. All mice were seeded with AD crude extract
at the age of 10 weeks and perfusion-fixed with 4% parafor-
maldehyde at the age of 22 weeks.
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Perfusion-fixed brains were processed at Neuroscience
Associates (Knoxville, TN) using MultiBrain technology.
Up to 25 mouse brains were embedded together and
freeze-sectioned at 35 mm in the coronal plane through the
entire brain. Every sixth section was subjected to AT8 immu-
nohistochemistry to reveal phosphorylated tau, and every
sixth section was stained with the Gallyas silver stain to
reveal NFT. Gallyas silver and AT8 positive neurons
(soma) were counted in ipsilateral and contralateral sides
of the hippocampus of all brains. All subregions of the hip-
pocampus were included, omitting the subiculum. Eight sec-
tions covering the dorsal and ventral hippocampus were
counted per brain (equivalent to A/P, 21.22 to 22.8 from
bregma). Results reflect the sum of positive neurons accu-
mulated over the eight sections. The Gallyas pathology
was quantified in the entorhinal cortex on the six most caudalFig. 1. Screening cascade and summary over the characterization of the phospho-
ease; IHC, immunohistochemistry; P3, sarkosyl-insoluble brain fraction; S1, solusections containing cerebral cortex. The ImageJ program
was used for quantification. Group variance was analyzed
using Bartlett’s test of equal variance. Because there was a
significant difference in variance between groups the
nonparametric Kruskal-Wallis test was used, followed by
Dunn’s multiple comparison test.3. Results
3.1. Generation and characterization of tau pS396 and
pS404 antibodies3.1.1. Selection of clones
Mouse monoclonal antibodies were generated (Fig. 1) by
immunization with P30-pS396/pS404-tau peptide, and 150
clones were initially selected based on binding activity to
the pS396/pS404-tau peptide. Subsequently, the panel oftau antibodies described in this article. Abbreviations: AD, Alzheimer’s dis-
ble brain fraction; WB, Western blot.
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peptide tau (p396 epitope only), full-length in vitro phos-
phorylated tau, and AD tissue. Sequencing revealed three
of these antibodies (C10.2, C5.2, and C8.3) to have nearly
identical complementarity determining region leaving
C10.2 (IgG1k) and D1.2 (IgG2k) from a different series
for further characterization. From the same immunizations,
C10.1 (IgG1k) was selected based on pS404-tau binding.
The apparent affinities (IC50) of the antibodies to the
pS396/pS404-tau peptide were determined in a
competition binding assay for D1.2 (19 nM), C10.2
(66 nM), and C10.1 (24 nM) (Supplementary Fig. 1A).Fig. 2. Antibody selectivity toward pS396 or pS404 tau (386–408) peptides and d
screened for binding on tau (386–408)-pS396/pS404–coatedMSD plates. Data pres
and C10.2 bind to tau phosphorylated at S396 but not to nonphosphorylated or S4
binding but not S396. (B) Dot blot demonstrating selective binding by D1.2 and
rTg4510 and AD brains compared with tTA littermates and HC brain fractions. (C)
tex. Photomicrographs are representative of three AD and three HC cases, images
solution binding of antibodies to AD brain. Insoluble P3 tau fraction was mixed wi
MSD plates. Data are presented as percent P3 binding when preincubated with incr
At the given antibody concentrations, only C10.2 resulted in a concentration-dep
healthy control; MSD, Meso Scale discovery; PBS, phosphate buffered saline.3.1.2. Antibody specificity and selectivity
Antibody specificity toward S396 and S404 phosphoryla-
tion sites was assessed by the ability of monophosphorylated
peptides to compete with antibody binding to pS396/pS404-
tau. Both D1.2 and C10.2 bindings were inhibited by the tau
peptide phosphorylated at S396 but not when monophos-
phorylated at S404, whereas competition of C10.1 binding
requires phosphorylation of S404 but not of S396
(Fig. 2A). The antibodies were further characterized for their
ability to bind the soluble S1 or sarkosyl-insoluble P3 tau
fractions obtained from AD and HC brains or from
rTg4510 and tTA control brains by dot blot analysis. Bothisease material. (A) Antibodies were mixed with the indicated peptides and
ented as percentage binding in relation to PBS control incubation. Both D1.2
04-phosphorylated tau, whereas C10.1 requires phosphorylation of S404 for
C10.2 to soluble (S1) and sarkosyl-insoluble (P3) fractions isolated from
Immunohistochemical staining of AD and HC brain sections of frontal cor-
from a single AD and a single HC case are shown. Scale bar: 50 mm. (D) In-
th antibodies D1.2, C10.2, C10.1, or PHF13 before binding to C10.2-coated
easing amounts of antibody in relation to P3 binding without added antibody.
endent decrease in binding. Abbreviations: AD, Alzheimer’s disease; HC,
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rTg4510 brains and S1 from rTg4510 mice (Fig. 2B). This
is in line with antibodies D1.2 and C10.2 binding preferen-
tially to hyperphosphorylated tau from human AD brain or
rTg4510 mouse brains demonstrated by Western blot
(Supplementary Fig. 2). C10.1 only binds normal phosphor-
ylated tau protein in the S1 fractions (Supplementary Fig. 2).
By immunohistochemistry, NFTs, neuropil threads, and
dystrophic neurites were detected in AD brain sections by
the D1.2 and C10.2 antibodies (Fig. 2C). No immunoreac-
tivity was detected in HC sections. In contrast, C10.1 did
not stain AD sections. In subsequent assays, C10.1 served
as negative control.
3.1.3. Antibody affinity to tau peptides
Antibodies D1.2 and C10.2 were subjected to detailed
binding kinetics analysis using surface plasmon resonance
binding on the Biacore system (Table 1). D1.2 and C10.2
bind the tau (386–408)-pS396 with an affinity (Kd) of 11
and 27 nM, respectively. In agreement with surface plas-
mon resonance, MSD-based analysis showed that D1.2
and C10.2 bind equally well to diphosphorylated peptides
as well as to monophosphorylated S396 (Fig. 2A). Both
antibodies showed similar binding to pS396-tau peptide.
We developed an inhibition binding assay using sarkosyl-
insoluble P3 tau isolated from AD brains in the solution
phase, based on the hypothesis that P3 material contains
tau in a seeding competent conformation and the solution
phase mimics the extracellular conditions. Antibody binding
potency toward the P3 AD fractions was assessed using an
inhibition assay with MSD plates coated with C10.2. We
have compared C10.2 and D1.2 with PHF13 and demon-
strated that only C10.2 showed potent inhibition, with an
IC50 of 1.2 nM. As expected, the C10.1 was not able to
compete the antigen capture in C10.2 plates in the solution
phase (Fig. 2D), because C10.1 did not bind to hyperphos-
phorylated tau in the P3 fraction (Supplementary Fig. 2C).
This contrasts with antibody competition using in vitro phos-
phorylated tau-441 for antigen capture in C10.2-coated
plates where D1.2 (IC50; 50 pM), C10.2 (IC50; 104 pM),
and PHF13 (IC50; 758 pM) all compete with binding to
C10.2 (Supplementary Fig. 1B).
3.1.4. Immunodepletion of phosphorylated tau from
rTg4510 and AD brain extracts
To investigatewhether hyperphosphorylated or normal tau
is recognized by C10.2 and D1.2, crude extracts prepared
from rTg4510 and tTA mouse brains were immunodepleted
by either of the antibodies, and the residual extract was exam-
ined by Western blot. Both antibodies reduced the amount of
pS396 tau recognized byC10.2 by approximately 85%. There
was a minor effect on the total tau levels (detected by E1)
where only the hyperphosphorylation-specific 64 kDa band
was markedly reduced (Supplementary Fig. 3A).
The two antibodies were also tested for their ability to
remove tau species from AD and HC crude extracts. BothD1.2 and C10.2 removed most pS396 tau recognized by
C10.2 (approximately 90% of the Western blot signal),
including the typical pS396-positive AD smear
(Supplementary Fig. 3B). However, although depletion
with C10.2 efficiently removes the two distinct hyper-
phosphorylated tau bands (64 and 69 kDa), D1.2
left some residual 64 and 69 kDa tau being
recognized by C10.2. Overall, the depletion of hyper-
phosphorylated AD tau species using D1.2 and C10.2
only resulted in a small reduction in the total pool of
tau (Supplementary Fig. 3B). The immunodepleted
rTg4510 and AD brain extracts were subsequently used
in seeding experiments.
Collectively, our data demonstrate that although all three
antibodies bind peptide tau and full-length phosphorylated
tau, binding to AD and rTg4510 hyperphosphorylated tau
can only be achieved by C10.2 and D1.2 directed toward
pS396-tau and not by the pS404-tau specific C10.1.
Furthermore, C10.2 proved to be superior to D1.2 in
binding hyperphosphorylated tau in solution phase assay.3.2. Evaluation of C10.2, D1.2, and C10.1 effects on
in vitro seeding3.2.1. Tau seeding assay in HEK293 cells
We established an HEK cell–based seeding assay by tran-
siently overexpressing 0N4R-P301L human tau. In this
assay, tau aggregation was assessed either by an
aggregation-specific immunoassay or by Western blot anal-
ysis of the Triton X-100 insoluble tau, 3 days after adding
rTg4510 hard spin crude extracts (Supplementary
methods). The assay was used to measure the effects of
C10.2 immunodepletion on the seeding capacity of
rTg4510 extract. C10.2 immunodepletion resulted in 88%
reduction in aggregated tau (measured in Cisbio assay)
and 97% reduction in the pS396-positive insoluble tau
(measured by Western blot) (Supplementary Fig. 4A).
Next, we generated a stable HEK cell line expressing
the MTB repeats of human tau with P301L/V337M muta-
tions fused to green fluorescent protein and measured
seeding as fluorescent inclusion bodies on induction
with rTg4510 seeds (Supplementary methods). Preincu-
bation of the seeding material (rTg4510 hard spin
crude extract) with antibodies D1.2 or C10.2 results
in a concentration-dependent prevention of seeding
(Supplementary Fig. 4B). The maximum inhibition
achieved at the highest antibody concentration applied
(100 nM) was 86% for C10.2 and 35% for D1.2 with
calculated IC50 value of 4 nM for C10.2. We also demon-
strated that the effect of the C10.2 antibody can be abol-
ished by incubating the antibody with the tau (pS396/
pS404) peptide before adding it to the seeds and cells
(Supplementary Fig. 4C). As expected, C10.1 did not
modulate tau seeding in vitro.
Fig. 3. C10.2 and D1.2 reduce tau seeding in rTg4510 cortical neuronal cul-
tures without blocking the uptake of seeds into neurons. (A) Uptake of hu-
man tau from rTg4510 P3material was measured in tTA control neurons not
expressing human tau. The uptakewas measured as spots inside the cells de-
tected by the human tau-specific E1 antibody. Preincubation of P3 material
with C10.2, D1.2, or C10.1 does not prevent tau seed uptake. (B) In the same
experiment, the uptake of antibodies was detected by anti-mouse IgG and
measured as positive spots inside the neuronal cell bodies. Data in A and
B are presented as the mean6 SD and represents quantifications from three
wells with 20 fields/well analyzed. (C) Tau seeding was analyzed with the
Cisbio tau aggregation assay in rTg4510 neuron cultures. Before addition
of rTg4510 P3 seeding material to the neurons, it was preincubated with
C10.2, D1.2, C10.1, or control mouse IgG. An equal volume of P3 isolated
from tTA controls was added to the neuronal cultures as negative control not
inducing tau seeding. Neurons seeded at DIV7, medium changed at DIV11,
and cells lysed at DIV15. Data are presented as percentage aggregation
normalized to total protein in relation to IgG control, mean 6 SD from
=
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To further investigate how the tau antibodies interfere with
the seeding process we analyzed the uptake of antibody and
human tau from rTg4510 P3 fractions in tTA neurons express-
ing only endogenous murine tau. In line with previous reports
[12,31], human tau from P3 was taken up by the neurons
within 24 hours (Fig. 3A). The tau uptake was not affected
by the presence of tau antibodies (Fig. 3A) and immunofluo-
rescent detection revealed that bothC10.2 andD1.2 antibodies
were detected inside the neurons (Fig. 3B),whereasC10.1was
not detected in line with lack of binding to hyperphosphory-
lated tau from the P3 fraction (Supplementary Fig. 2C).
Neither was the control IgG detected in the neurons. These re-
sults suggest that only pS396-tau antibodies binding to
hyperphosphorylated tau in the P3 fraction were taken up
together with P3 tau by the neurons.
Next, we investigated whether hyperphosphorylated tau
from the P3 rTg4510 fraction can induce tau seeding in
rTg4510 neuron cultures. These cortical neurons show the
expression of the 4R0N human tau isoform with P301L mu-
tation in addition to murine tau (data not shown) and no hy-
perphosphorylated/aggregated tau was detected in neurons
cultured up to 4 weeks (data not shown). When neurons
were incubated with low concentrations of fibrillary tau spe-
cies (2 pg/mL) from the rTg4510 P3 fraction, aggregated tau
was observed by the Cisbio assay 8 days after the seeding
(Fig. 3C). Tau seeding did not result in impaired viability
of the neuronal cultures measured by MTT reduction test
(data not shown). When preincubating the P3 fraction with
C10.2 or D1.2 before adding to the neurons, the tau aggrega-
tion was reduced approximately 50% and 15%, respectively
(Fig. 3C). The preincubation with C10.1 did not prevent tau
aggregation in the neurons (Fig. 3C).3.3. Evaluation of C10.2 and D1.2 effects in in vivo
seeding3.3.1. Establishment of the rTg4510 mouse seeding model
We seeded tau pathology in vivo in short-term doxycy-
cline-treated rTg4510 mice [34]. Without juvenile doxycy-
cline treatment, tau pathology develops at an early age
(10–16 weeks) [34]. By a transient doxycycline treatment
at age from conception to 3 weeks the tau pathology was de-
layed approximately to the age of 24 weeks, and thus pre-
senting a window for studying seeding-induced tau
pathology. Seeding of tau pathology was induced by intra-
hippocampal injection of rTg4510 crude brain extracts
(Fig. 4A). To determine the optimal time for the develop-
ment of pathology, seeding was evaluated by AT8 immuno-
histochemistry (Fig. 4B, C) and Gallyas silver stain5 to 15 wells from 2 to 4 independent experiments. One way ANOVA
Newman-Keuls multiple comparison test, *P , .05; ***P , .001;
n 5 10–60. Abbreviations: ANOVA, analysis of variance; DIV, days
in vitro; IgG, immunoglobulin G; SD, standard deviation.
Fig. 4. Seeding model in rTg4510 mice. (A) Doxycycline-treated rTg4510 mice with delayed tau phosphorylation were unilaterally injected in hippocampus at
age 10 weeks with crude extracts prepared from rTg4510 or tTA brains. Mice were housed for 4, 8, or 12 weeks and brains were processed for AT8 immuno-
histochemistry (B) to reveal phosphorylated tau; or the Gallyas silver stain (D, F) to reveal neurofibrillary tangles. Most seeded tau pathology developed bilat-
erally in the hippocampus and in the perirhinal and lateral entorhinal cortices. Scale bar in B and D: 50 mm and in F: 200 mm. (C, E) AT8- and Gallyas-positive
neurons (soma) were counted on ipsilateral and contralateral sides of the hippocampus. Data represent accumulated number of positive neurons from eight cor-
onal sections from each animal and mean6 SEM. (G) Gallyas-positive cells were quantified in the entorhinal cortex and data represent accumulated number of
positive neurons from six coronal sections from each animal and mean6 SEM. N5 3 animals per time point. Nonparametric Kruskal-Wallis test and Dunn’s
multiple comparison test, *P , .05; **P , .01; ***P , .001; ****P , .0001. Abbreviation: SEM, standard error of the mean.
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cellular tau pathology developed in mice receiving rTg4510
extracts, whereas no or only limited pathology was observed
in mice injected with control tTA extract (Fig. 4C, E, G). Tau
pathology also developed in contralateral sides of hippocam-
pus and lateral entorhinal cortex. Tau pathology increased
over time and at 12 weeks there was a significant difference
in the tangle load between mice injected with tTA and
rTg4510 material in all regions quantified (Fig. 4C, E, G).
At this time-point (i.e., at 22 weeks) we observed a weak
AT8 signal in the hippocampus of rTg4510 mice receiving
control tTA extracts (data not shown). This indicates that
at this age, the overexpressed human tau begins to form
detectable pretangles without the addition of seeds. Thus,
we did not explore longer time-points and subsequently
used the 12-week end point. This is in concordance to previ-
ous reports of other in vivo tau seeding models [9,11,37].
3.3.2. Seeding with immunodepleted material
We explored the role of specific tau species in vivo by per-
forming tau seeding with rTg4510 and AD crude brain ex-Fig. 5. In vivo seeding activity is reduced by depleting the rTg4510 and AD
extracts with tau (p396) antibodies. Tau or control antibodies were used to
immunodeplete crude extracts from (A) rTg4510 brains or (B) AD brains.
The depleted extracts were injected unilaterally in hippocampus at age 10
and 12 weeks after injection, the number of AT8- or Gallyas-positive neu-
rons was counted in the ipsilateral hippocampus. Data presented as accumu-
lated number of positive neurons from eight sections from each animal and
mean 6 SEM, N 5 7–10 (A) and N 5 12–13 (B). Nonparametric Kruskal
Wallis and Dunn’s multiple comparison test, *P, .05; **P, .01. Abbrevi-
ations: AD, Alzheimer’s disease; SEM, standard error of the mean.tracts depleted by either the D1.2 or the C10.2 antibody
(as described in Section 3.1.4). Twelve weeks after injection
with D1.2 or C10.2 depleted extracts only low levels of seed-
ing were observed in the rTg4510 mouse (Fig. 5A, B). In
contrast, by depletion of rTg4510 extract using the total
tau antibody Tau5 (predominantly removing normal
55 kDa tau but only 20% of pS396-tau Supplementary
Fig. 3A) the seeding activity was retained. We used Tau5
and C10.2 in combination to perform a maximal tau deple-
tion; however, no additional reduction in seeding was
observed (Fig. 5A).
3.3.3. Effect of antibody treatment on seeding capacity
Antibodies D1.2 and C10.2 were also evaluated in a ther-
apeutic setting in rTg4510 mice seeded with rTg4510 crude
extracts (Fig. 6A). The mice were dosed weekly with anti-
body (15 mg/kg, ip) for 14 weeks, starting 2 weeks before
the seeding and continued until euthanized. Plasma levels
of the antibodies were greater than 100 mg/mL at the time
of seeding (data not shown). C10.2 treatment reduced the
seeding by 74% (P , .01) and D1.2 treatment reduced the
seeding by 66% (P , .05).
Furthermore, we explored the mechanism of inhibition by
C10.2 in rTg4510 mice seeded with AD crude extracts by
applying three different dosing paradigms (Fig. 6C). We
compared dosing throughout (1) the entire seeding period
(14 weeks, full), (2) start 4 weeks after seeding (post), and
(3) C10.2 treatment only for 3 weeks, starting 2 weeks
before injection (pre). Prevention of seeding and develop-
ment of pathology was only observed when there was anti-
body (C10.2) exposure at the time of seed injection (full
and pre) (Fig. 6D). Dosing of C10.2 4 weeks after seeding
with AD brain material (post) had no effect. These data sug-
gest that the antibody interacts with extracellular seeds and
thereby prevents seeding and further development of tau pa-
thology.4. Discussion
The epitope defined by phosphorylation of S396 in tau
has been heavily implicated in AD-associated tau pathology
[38] and provides a valuable target for the development of
therapeutic antibodies to capture tau and prevent spreading
of tau pathology. Here, we describe the generation and char-
acterization of such an antibody.4.1. pS396-tau-specific antibodies C10.2 and D1.2
selectively recognize pathologic tau in AD and rTg4510
brain material
The binding of C10.2 and D1.2 to phospho-tau peptides
(pS396) and (pS396/pS404) showed similar affinity (11–
31 nM) indicating that both antibodies specifically recog-
nize the pS396-tau epitope independently of the pS404
residue. Binding to in vitro phosphorylated tau-441 is
also similar for C10.2 (IC50; 104 pM) and D1.2 (IC50;
Fig. 6. C10.2 and D1.2 treatment decreases tau seeding in the rTg4510 model. (A, B) Mice were dosed once weekly with 15 mg/kg antibody beginning 2 weeks
before hippocampal seeding with rTg4510 crude extracts. The treatment was continued until sacrifice at age 22 weeks. Gallyas-positive cells were quantified in
the ipsilateral hippocampus revealing reduced tangle pathology by C10.2 (74%) and D1.2 (66%). (C, D) Different dosing paradigmswere applied to the rTg4510
seedingmodel by C10.2-treatment before seeding (pre; 8–10 weeks old), after seeding (post; 14–22 weeks old), or full treatment at age from 8 to 22 weeks. In all
groups, seeding was performed by injection of AD crude extract at age 10 weeks. Control IgG-treated mice served as positive controls. Data presented as accu-
mulated number of positive neurons from eight sections from each animal and mean6 SEM, N5 20–22 for the rTg4510 injected groups and N5 2 for the tTa
group (B) and N5 14 (D). Nonparametric Kruskal-Wallis and Dunn’s multiple comparison test, *P, .05; **P, .01. Abbreviations: AD, Alzheimer’s disease;
IgG, immunoglobulin G; SEM, standard error of the mean.
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relative to the peptides may reflect a more efficient display
of the antibody-binding epitope in the full-length tau.
Both antibodies also recognize hyperphosphorylated tau
in AD brain material in the immobilized phase (dot blot,
Western blot). Notably, only C10.2 exhibits an effective
binding in solution phase competition assays toward hu-
man AD P3 with an IC50 of 1.2 nM. This suggests that
insoluble human AD tau (P3), when in solution phase,
presents a conformation of the pS396 epitope recognized
by C10.2 but not by D1.2. The binding mode of a
pS396-tau–specific antibody in complex with a tau
model-substrate peptide has been determined by x-ray
crystallography [39]. This crystal structure demonstrates
the antibody C5.2 (variant of antibody C10.2) binds to a
unique extended conformation of the tau peptide chain,
stabilized by an interaction between the Y394 and the
pS396 side chains. The cryo-electron microscopy crystal
structure of AD-generated MTB domains has been deter-
mined recently showing the b-sheet structure of the proto-
fibrils [14]. The S396 epitope lies within the flanking
region of the b-sheet structure and phosphorylation at
S396 may stabilize this conformation.The antibody C10.1 specifically recognizes the pS404
epitopes in tau peptides, but does not bind hyperphosphory-
lated tau isolated from rTg4510 and AD brains. Further-
more, C10.1 is not able to block seeding in HEK293 and
neuronal in vitro assays, indicating that this antibody is not
able to efficiently engage with tau seeding material. Howev-
er, others have explored the therapeutic utility of targeting
the pS404 epitope. Ittner et al. [29] conducted a passive
immunotherapy study using presumed pS404-specific anti-
bodies in two transgenic tau mouse models. They report a
reduction in tau pathology after treatment with an IgG2a
but not with an IgG1 isotype mouse antibody. This suggests
that recruitment of microglia through antibody immune
complexes plays a role for clearance of tau pathology by
these tau antibodies.4.2. Antibody C10.2 recognizes the in vitro seeding-
competent pool of tau
C10.2 is differentiated from D1.2 and PHF13 antibodies
by its ability to bind phosphorylated tau in the AD P3 solu-
tion phase competition assay, whereas the three antibodies
show similar binding to in vitro phosphorylated tau. This
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specific antibodies suggests that there is a variation in the
phospho-tau antigenic epitope display. Concurring with P3
solution phase competition binding data, C10.2 shows
more efficient depletion in the pS396 bands in AD extracts
compared with D1.2, when examined by Western blot anal-
ysis. In conjunction with this, D1.2 demonstrates limited
anti-seeding effects in rTg4510 primary neurons and human
tau-overexpressing HEK293 cells. Thus, we have demon-
strated that the pool of tau recognized by C10.2 constitutes
most of the in vitro seeding-competent tau observed in the
human AD brain.
Earlier studies [13] identified small fibrils of hyper-
phosphorylated tau as the main seeding competent species
in AD models. Although these species may be highly het-
erogeneous and composed of several proteolytically di-
gested fragments of tau, it appears from the present
study that C10.2 will recognize most of these tau species.
Recent structural studies suggest that the folding core for
the main seeding species in tau is constituted of the MTB
domains (residues 306–378) [14]. This seeding core may
not be fully accessible to antibodies in its aggregated
form. For this reason, the optimal antibody for therapeutic
intervention should recognize the more exposed MTB
flanking regions, like C10.2.4.3. pS396-tau antibodies prevent in vivo tau seeding
We used our rTg4510 model with delayed onset of tau pa-
thology to explore anti-seeding properties of the antibodies.
Our studies demonstrate that C10.2 and D1.2 antibodies
effectively prevent the development of the tau pathology
induced by injection of crude rTg4510 or AD brain extracts
into the hippocampus. This was demonstrated both by im-
munodepletion and by systemic antibody treatment. The
specific binding properties of C10.2 shown in the in vitro
seeding models do not translate into superior in vivo efficacy
over the D1.2 antibody. We attribute this to a much lower
sensitivity of this model in comparison, that is, a higher
load of seeding material was needed to obtain a measurable
histologic readout. Furthermore, the in vivo studies were
conducted with an excess of antibody, and breakdown of
the blood-brain barrier during surgery may contribute to an
increased local exposure. The predictive and translational
value of these models remains to be demonstrated in clinical
trials. Others have demonstrated that the pS396 targeting
antibody PHF13 can reduce seeding in P301S mice (PS19)
seeded with artificial MTB preformed tau fibrils (K18PL)
[24]. In our study, PHF13 and D1.2 show similar binding
profiles. Both bind full-length phosphorylated tau but not
the AD P3 fraction in a solution phase assay.
We observe no evidence that the antibodies are indepen-
dently taken up by neurons and elicit their action within the
cell. However, we do observe that antibody-tau complexes
are taken up by the primary neuronal cultures, as earlier
demonstrated [31]. Thus, the effect on pathology observedin vivo may reflect inability of antibody-decorated brain ex-
tracts to induce seeding and aggregation in the host cell. This
is supported by the observation that prevention is only
possible when there is C10.2 exposure at the time of seed in-
jection and not when the antibody is dosed after the tau seeds
have been taken up. The role of active clearance mechanisms
via microglia and astrocytes has not been investigated in this
study.
The rTg4510 seeding model presented here demon-
strates antibody-induced inhibition of tau seeding but
not secondary propagation to other neurons. Endogenous
phosphorylation of the human tau transgene in rTg4510
mice supersedes the time point where we can expect to
detect an interneuronal spread of pathology. A longer in-
terval than the 12 weeks that is achievable in the present
model is likely required, as has been previously demon-
strated [40].
4.4. Therapeutic potential
In light of failed clinical trials using small molecules to
inhibit tau phosphorylation (glycogen synthase kinase 3
inhibitor [41]) or aggregation (leuco-methylthioninium
bis [42]), immunotherapy targeting the propagation of
tau pathology offers an attractive new endeavor to treat
AD. Recent studies highlight differences in neutralization
efficiency of tau seeds by a panel of antibodies, suggesting
that not all tau epitopes present optimal targets for immu-
notherapy [30]. Seeding and spreading is believed to be an
ongoing process in the AD brain and our data indicate that
C10.2 would specifically target tau seeds and neutralize
these when present in the extracellular space. A human-
ized mouse monoclonal antibody (based on C10.2) specif-
ically targeting hyperphosphorylated tau has entered
clinical development for the potential treatment of AD.5. Conclusions
We have generated a murine monoclonal antibody, C10.2,
that specifically recognizes the pS396 tau epitope and selec-
tively binds AD and rTg4510 brain material. C10.2 exhibits
unique solution phase binding properties in interaction with
AD hyperphosphorylated tau. C10.2 potently prevents tau
seeding in cellular and in vivo assays. To sum up, our studies
suggest that C10.2 uniquely recognizes the pS396 epitope as
it is presented in AD brains, and thus provides a promising
candidate for immunotherapy.
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1. Systematic review: Hyperphosphorylated tau has
been established as a hallmark of Alzheimer’s dis-
ease (AD) in the scientific literature. Specific phos-
phorylation sites appear to be more frequently
phosphorylated in hyperphosphorylated pathologic
tau associated with disease.
2. Interpretation: Hyperphosphorylated tau forms a key
seeding species in seeding and spreading of tau pa-
thology in AD and other tauopathies. The heteroge-
neous pool of hyperphosphorylated tau can be
targeted with phospho-tau specific monoclonal
antibodies. Phospho-serine 396 (pS396) specific
anti-tau antibodies have been generated, which
target the complete heterogeneous pool of hyper-
phosphorylated tau.
3. Future directions: A humanized version of one of
these antibodies (C10.2) will soon enter into clinical
trials for the treatment of AD.References
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